Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMAVERA: 1-Dose Bivalent HPV Vaccine vs 3-Dose Quadrivalent Vaccine
NCT03728881Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2019
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number Seropositive for HPV16 at 36 Months, Immunogenicity for HPV16 of One Dose of Bivalent HPV Vaccine in Girls Compared to Three Doses of Quadrivalent HPV Vaccine in Women at 36 months and 6 more. Started Apr 2019; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03728881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728881.